The coronavirus disease 2019 (COVID-19) pandemic has claimed several thousand lives since the first case was described in Wuhan, China, in December 2019.1 This has mainly been related to pulmonary complications presumed to be due to infection-associated inflammation and the resulting cytokine storm.2 Abnormal hemostasis was recognized early in the profile of these patients, with raised D-dimer being the most frequent abnormality in more than 70% of admitted patients with remarkably minimal changes in the remaining commonly measured hemostasis parameters (e.g., minimal prolongation of prothrombin time [PT] in some patients, and mild reduction in platelet count [almost all above 100 × 10^9/L] but with markedly raised fibrinogen levels and no schistocytes3). As may be anticipated from these laboratory findings, bleeding has not been a notable feature of this illness. In early reports, these changes were considered consistent with disseminated intravascular coagulation (DIC) or sepsis-induced coagulopathy (SIC).3,4 There is increasing recognition that the COVID-19-associated hemostasis abnormality (CAHA) may instead be resulting in localized thrombosis in the lungs, which has been reinforced by the fact that timely anticoagulation can be successful in reducing mortality of seriously unwell patients.4,5 This has led to recommendations for early intensive anticoagulation, in the absence of absolute contraindications, for all COVID-19 patients requiring hospitalization.6 Very recent postmortem reports have in fact confirmed this hypercoagulable state, with evidence of pulmonary thrombi, mostly microvascular, in all the four decedents evaluated.7 Recognizing the basis of the predominant lung pathology linked with the rapid clinical deterioration that is often unresponsive to ventilatory assistance and supportive care is critical to devising the interventions aimed at reducing mortality in these patients.

### Immunothrombosis and Pulmonary Microthrombi

The hemostasis and immune systems have always been linked to one other. In evolutionary biology, it was recognized that both these systems shared the same purpose.8 It may be considered that a blood clot formed at the site of wound limits the loss of the most important constituent, the blood. But also, equally importantly, it stops any microorganisms invading the circulation through the breached vessel wall. Various components of the hemostatic system contribute to this immune function. Thrombin is the key player which plays a central role in linking the clotting pathways to the innate immune system.9 In addition, crosstalk between the various other coagulation factors, including the kallikrein-kininogen pathways on one side and cytokines, complement system, and the innate immune system on the other, is also well established.10,11 The main cellular component of the hemostatic system, the platelet, also plays a key role in this area. Several of its granular constituents are microbicidal and chemotactic; both functions may play a more important role than hemostasis in the setting of infections.12

The concept of a localized coagulation system in the lung as part of host defense or "bronchoalveolar hemostasis" is not recent.13 Indeed, the presence of a localized hemostatic system has been recognized for many years and attempts to modulate this in pathological conditions have been tried for at least a decade.14-16 These measures have not always been successful and localized pulmonary microthrombi continue to cause mortality in severely ill patients.17

What then is the pathophysiology of pulmonary microthrombi in patients with COVID-19? Is it the intense inflammation related to the viral invasion of the lungs which triggers hemostasis activation? The growing evidence strongly suggests that some of the clinical features of COVID-19 infection...
(like hypoxemia) are driven by a localized thrombotic phenomenon where both platelets and endothelium come together to initiate thrombosis. Endothelial cells constitute almost a third of the cells in the alveolar component of the lungs and have the key receptors for the SARS-CoV-2 including the angiotensin-converting enzyme-2 receptors. In addition to this well-described receptor, several others, including transmembrane serine protease 2 and sialic acid receptors, are shared by both the SARS-CoV-2 and the endothelial cells. Formation of thrombi in the microvasculature could thus be a part of the physiological effort to limit the viral invasion. Marked endothelial activation secondary to the inflammation could release a large amount of von Willebrand factor (VWF), which could then swamp the VWF-cleaving protease, ADAMTS-13, leading to platelet aggregates that could also contribute to microthrombi. Although this feature is characterized in the well-known systemic microangiopathic hemolytic disorders, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, in COVID-19, this process is limited to the lungs, and systemic evidence of microangiopathy may not be evident in all cases. Limited thrombotic microangiopathy (TMA) can present as pulmonary hypertension, as reported in patients with TMA secondary to Cobalamin C deficiency and pediatric stem-cell transplantation. Similar organ-limited TMA is very familiar to renal pathologists.

Pulmonary Microthrombi versus Pulmonary Emboli

It is important to distinguish pulmonary microthrombi from pulmonary emboli in COVID-19 patients. Clinically, there are several situations where thrombi in the lungs could be overlooked in patients presenting with COVID-19 symptoms to hospital:

- Attribution of respiratory symptoms to severe pneumonia.
- Increasing oxygen requirements in patients admitted to hospital attributed to worsening pneumonia or acute respiratory distress syndrome.
- Inability to perform imaging due to work overload on the radiology department or the need for social distancing.
- Absence of deep vein thrombosis (DVT) in the limbs does not imply absence of pulmonary thrombi.

It is well known that over half of the patients otherwise identified to have pulmonary embolism in the pre-COVID-19 era also have evidence of DVT in the lower limbs. For this reason, in patients in whom computed tomography imaging may be less desirable (e.g., pregnancy or severe renal impairment), some clinicians (not widespread practice) perform ultrasound Doppler of the lower limbs to check for thrombi and treat with therapeutic anticoagulation, if identified. However, this is not the case in patients with COVID-19, where DVT is not found in most patients, and pulmonary microthrombi are the result of local hypercoagulability, and not secondary to embolization from the lower limbs. For this reason, ultrasound surveillance may not be enough to identify such microthrombi. Patients who require critical care input, however, could subsequently develop venous thrombosis, which can then embolize to the lungs, further aggravating the lung dysfunction. Despite a critically ill patient being at a very high risk of thrombosis due to various reasons (including immobilization, underlying risk factors, muscle paralysis from sedation, and the use of vasoactive drugs), the diagnosis of pulmonary embolism can still be missed. This is not helped by the fact that prophylactic anticoagulation has high failure rate in critically ill individuals, but could be even worse in the extremely activated clotting system as seen in COVID-19.

Does It Matter Whether It Is Pulmonary Microthrombi or Pulmonary Emboli?

A recent publication looked at the structure and composition of thrombi and emboli using high-resolution scanning electron microscopy. The pulmonary emboli mirrored the most distal part of venous thrombi from which they originated. Also, the proportion of red cells in venous thrombi and pulmonary emboli was much higher than in arterial thrombi and more fibrin bundles were observed in the latter compared with the former. This finding is not clinically useful yet, but if we consider that platelets play a major role in pulmonary microthrombi compared with pulmonary emboli, it may be necessary to treat these patients with antiplatelet agents in addition to anticoagulants (the latter has proven track record only in those with pulmonary emboli). These antiplatelet drugs block platelet activation and may include conventional antiplatelet agents like aspirin or clopidogrel or intravenous forms like prostacyclin. Perhaps anti-inflammatory and anticomplement therapies are the answer to addressing the pathophysiology of pulmonary microthrombi in COVID-19, as the trigger for the microangiopathy is the inflammatory component. Very interestingly, immunocompromised individuals have been suggested to have had less pulmonary complications when infected with COVID-19. Also, may there be a role for nebulized or localized antithrombotic therapies, which can impact microvascular hemostasis as the coagulation system is activated and largely limited to the lungs at the alveolar level.

Current Antithrombotic Strategies for Pulmonary Microthrombi

There is consensus now that all patients admitted to hospital with COVID-19 receive prophylactic anticoagulation. It is also certain that those who have a confirmed pulmonary emboli receive therapeutic anticoagulation. Several trials have been established, looking at randomizing patients to receive prophylactic or therapeutic anticoagulation based on various clinical and laboratory markers, and results are eagerly awaited. Still several interesting questions remain:

- Should low-dose anticoagulants be considered for patients who may have a prothrombotic tendency and are currently in self-isolation but do not have severe symptoms of COVID-19?
- Are patients who are already on anticoagulants for previous thromboembolic episodes, mechanical heart valves,
or atrial fibrillation protected from severe disease and complications if they indeed get infected with the SARS-2 corona virus?

- Will patients with underlying severe bleeding disorders such as hemophilia or Glanzmann thrombasthenia have less severe lung complications?
- Since there is a crucial link between inflammation and thrombosis, more so in COVID-19 patients, are patients who are on immunosuppressants less likely to get severe pulmonary disease and complications?
- Is there a role for antiplatelet agents in patients who progress to more severe disease while on therapeutic anticoagulation, since activated platelets are pathogenic in the lung inflammation?
- Where and how should anticomplement and anti-inflammatory therapies be used in patients with COVID-19, with the intention of dampening the coagulation response?
- Should patients who have recovered from severe COVID-19 after being in critical care units be considered for long-term anticoagulation with low-dose anticoagulants, like those patients who had massive pulmonary embolism in the pre-pandemic era?

**Conclusion**

In summary, it is important to recognize that COVID-19-associated hemostasis abnormalities, which we would term as “CAHA,” represent a localized thrombotic phenomenon, which thus requires specific assessment and an appropriate therapeutic response (see Fig. 1). Health care providers need to be cognizant of the significant possibility of pulmonary microthrombi in these patients and should keep a low threshold for investigating this complication in all patients. This is important because pulmonary thrombosis and pulmonary embolism may need different treatments. In the case of pulmonary microthrombi, this may be a combination of treatments in addition to anticoagulants. We are sure to win in this battle against an unseen but now well-known virus but should aim to learn a large amount quickly, regarding both its pathology and the potential therapies to limit short-term and long-term morbidity and mortality in infected patients.

**Conflict of Interest**

None.
Acknowledgment
We would like to thank Srujan K. Marepally for his help with the figure.

References